The clinical experience of anti-IgE antibody treatment in patients with refractory chronic urticaria

Similar documents
012임수진

Lumbar spine

< D B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A E687770>

1..

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie

歯1.PDF

ÀÇÇа�ÁÂc00Ì»óÀÏ˘

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있

( )Kju269.hwp

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

590호(01-11)

γ

(Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern (Micro- Environment) Re



서론 34 2

12이문규

( )Jkstro011.hwp

한국성인에서초기황반변성질환과 연관된위험요인연구

Journal of Educational Innovation Research 2017, Vol. 27, No. 2, pp DOI: : Researc

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

Jkcs022(89-113).hwp

A 617

기관고유연구사업결과보고

Treatment and Role of Hormaonal Replaement Therapy

Can032.hwp

hwp

27 2, 1-16, * **,,,,. KS,,,., PC,.,,.,,. :,,, : 2009/08/12 : 2009/09/03 : 2009/09/30 * ** ( :

00약제부봄호c03逞풚

Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:

(

Journal of Educational Innovation Research 2018, Vol. 28, No. 4, pp DOI: * A Research Trend

139~144 ¿À°ø¾àħ



<35BFCFBCBA2E687770>

페링야간뇨소책자-내지-16

04-다시_고속철도61~80p

03이경미(237~248)ok

DBPIA-NURIMEDIA

Rheu-suppl hwp

. 45 1,258 ( 601, 657; 1,111, 147). Cronbach α=.67.95, 95.1%, Kappa.95.,,,,,,.,...,.,,,,.,,,,,.. :,, ( )


<30382EC0C7C7D0B0ADC1C22E687770>

노인정신의학회보14-1호

16(2)-7(p ).fm

김범수

황지웅

04조남훈

대한한의학원전학회지26권4호-교정본(1125).hwp

DBPIA-NURIMEDIA


YI Ggodme : The Lives and Diseases of Females during the Latter Half of the Joseon Dynasty as Reconstructed with Cases in Yeoksi Manpil (Stray Notes w

,......

서론


:,,.,. 456, 253 ( 89, 164 ), 203 ( 44, 159 ). Cronbach α= ,.,,..,,,.,. :,, ( )

Vol.259 C O N T E N T S M O N T H L Y P U B L I C F I N A N C E F O R U M

Àå¾Ö¿Í°í¿ë ³»Áö

Journal of Educational Innovation Research 2019, Vol. 29, No. 2, pp DOI: 3 * Effects of 9th

54 한국교육문제연구제 27 권 2 호, I. 1.,,,,,,, (, 1998). 14.2% 16.2% (, ), OECD (, ) % (, )., 2, 3. 3


원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 연세대학교대학원 의학과 남상현

untitled

388 The Korean Journal of Hepatology : Vol. 6. No COMMENT 1. (dysplastic nodule) (adenomatous hyperplasia, AH), (macroregenerative nodule, MR

부속

44-4대지.07이영희532~

전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II)

Journal of Educational Innovation Research 2017, Vol. 27, No. 3, pp DOI: : A basic research

(01) hwp

1. 서론 1-1 연구 배경과 목적 1-2 연구 방법과 범위 2. 클라우드 게임 서비스 2-1 클라우드 게임 서비스의 정의 2-2 클라우드 게임 서비스의 특징 2-3 클라우드 게임 서비스의 시장 현황 2-4 클라우드 게임 서비스 사례 연구 2-5 클라우드 게임 서비스에

#Ȳ¿ë¼®


Journal of Educational Innovation Research 2018, Vol. 28, No. 1, pp DOI: * A Analysis of


03-서연옥.hwp

11¹ÚÇý·É

자기공명영상장치(MRI) 자장세기에 따른 MRI 품질관리 영상검사의 개별항목점수 실태조사 A B Fig. 1. High-contrast spatial resolution in phantom test. A. Slice 1 with three sets of hole arr


<31372DB9CCB7A1C1F6C7E22E687770>



27 2, * ** 3, 3,. B ,.,,,. 3,.,,,,..,. :,, : 2009/09/03 : 2009/09/21 : 2009/09/30 * ICAD (Institute for Children Ability

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

歯채민병.PDF

???? 1

Journal of Educational Innovation Research 2019, Vol. 29, No. 1, pp DOI: * Suggestions of Ways

,......

182 동북아역사논총 42호 금융정책이 조선에 어떤 영향을 미쳤는지를 살펴보고자 한다. 일제 대외금융 정책의 기본원칙은 각 식민지와 점령지마다 별도의 발권은행을 수립하여 일본 은행권이 아닌 각 지역 통화를 발행케 한 점에 있다. 이들 통화는 일본은행권 과 等 價 로 연

975_983 특집-한규철, 정원호

2009;21(1): (1777) 49 (1800 ),.,,.,, ( ) ( ) 1782., ( ). ( ) 1,... 2,3,4,5.,,, ( ), ( ),. 6,,, ( ), ( ),....,.. (, ) (, )

_ _ Reading and Research in Archaeology. _ Reading and Research in Korean Historical Texts,,,,,. _Reading and Research in Historical Materials from Ko

Journal of Educational Innovation Research 2018, Vol. 28, No. 1, pp DOI: * A Study on the Pe

<313120B9DABFB5B1B82E687770>

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA

<BFACBCBCC0C7BBE7C7D E687770>

아태연구(송석원) hwp

7 1 ( 12 ) ( 1912 ) 4. 3) ( ) 1 3 1, ) ( ), ( ),. 5) ( ) ). ( ). 6). ( ). ( ).

04_이근원_21~27.hwp

Transcription:

The Clinical Experience of Omalizumab Treatment In Patients with Refractory Chronic Urticaria Young-Hee Nam, 1 Joo-Hee Kim, 2 Hyun Jung Jin, 3 Eui-Kyung Hwang, 4 Yoo-Seob Shin, 4 Young-Min Ye, 4 Hae-Sim Park 4* 1 Department of Internal Medicine, Dong-A University School of Medicine 2 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine 3 Department of Internal medicine, Yeungnam University College of Medicine 4 Department of Allergy and Clinical Immunology, Ajou University School of Medicine

Background Chronic urticaria (CU) is a skin disorder characterized by the spontaneous occurrence of widespread, transient wheals and pruritus, often accompanied by angioedema, persisting for 6 weeks. Zuberbier T et al. Allergy 2009;64:1417-26 DuBuske L et al. Am J Clin Dermatol 2007;8:271-83 Approximately 30% to 50% of patients with CIU reportedly produce IgG autoantibodies against either IgE or its highaffinity receptor (FceRI). Sabroe RA et al. J Allergy Clin Immunol 2002;110:492-9 Omalizumab, a recombinant humanized mab that selectively binds to IgE, inhibits the binding of IgE to the highaffinity IgE receptor (FceRI) on the surface of mast cells and basophils and reduces the number of FceRI receptors on basophils in atopic patients. Beck LA et al. J Allergy Clin Immunol 2005;1050:73-88

Several studies showed omalizumab is an effective for CU resistant to antihistamines. Kaplan AP et al. J Allergy Clin Immunol 2008;122:569-73 Saini S et al. J Allergy Clin Immunol 2011;128:567-73 Maurer M et al. J Allergy Clin Immunol 2011;128:202-9 Ferrer M et al. J Allergy Clin Immunol 2011;127:1300-2 Metz M et al. Allergy 2008;63:247-9 Spector SL et al. Ann Allergy Asthma Immunol 2007 Aug;99(2):190-3. However, there has been no report about efficacy and safety of omalizumab treatment in CU in Korean population.

Objective We investigated the efficacy of omalizumab in patients with CU symptomatic despite antihistamine therapy.

Subjects & Methods We conducted a retrospective study of patients who were treated with omalizumab for CU. Patients with refractory CU were defined as having symptoms for at least 6 weeks with persistent hives, and not controlled most days of the week, despite the use of a fourth-line therapy for more than 4 weeks, according to EAACI/GALEN guidelines. Omalizumab was administered every 2 or 4 weeks for 24 weeks, dosed according to the patient s body weight, and serum IgE levels. Urticaria activity score (UAS) and chronic urticaria-specific QOL (CU-QOL) questionnaires were completed every 4 weeks.

Treatment algorithm for CU Zuberbier T et al. Allergy 2009: 64: 1427 1443

Responses to omalizumab - Remission: no symptoms and no requirement for medications at least 4 weeks - Responsive: stepping down more than one level of therapy compared with baseline - Refractory: neither remission nor any symptom improvement during the treatment period

Urticaria Activity Score Parameters Score Wheal numbers None 0 Wheal distribution (% of BSA) 1 20 1 21 50 2 >50 3 None 0 <25% 1 25 50% 2 >50% 3 Wheal duration None 0 <4h 1 4 12h 2 >12h 3 Wheal size (diameter) None 0 <1cm 1 1 3cm 2 >3 cm 3 Pruritus None 0 Mild 1 Moderate 2 Severe 3 Ye et al. Clin Exp Dermatol 2012 in press

CU-QOL Lee et al. Korean J Asthma Allergy Clin Immunol 2010;30 Suppl 2:S384 문항질문 1 두드러기부위가가렵다 2 두드러기부위가부어불편하다 3 두드러기부위가화끈거리고열감이있어불편하다 4 밤에가려워서잠을설치게된다 5 두드러기로우울하다 6 두드러기로짜증이난다 7 두드러기로인해내모습이창피하다 8 두드러기로일상생활의만사가귀찮고의욕이없다 9 두드러기로인해내삶에대한자싞감이떨어진다 그렇지않았다 : 0 조금그랬다 : 1 보통이었다 : 2 꽤그랬다 : 3 많이그랬다 : 4 10 두드러기를일으킬지몰라새로운것 ( 음식이나환경등 ) 에노출되는것이두렵다 11 다른사람들과함께음식을먹어야하는상황에서눈치가보인다 12 두드러기를일으키는음식을가려먹어야하는것이힘들다 13 두드러기에대해다른사람들이놀려서스트레스를받는다 14 다른사람들이내두드러기에대해이야기하는것같아불편하다 15 두드러기로사람만나는것이꺼려진다 16 두드러기로내품위가떨어진것같은생각이든다 17 두드러기로인해다른사람에대해열등감을느낀다

Results

Table 1. Clinical characteristics of the subjects Clinical characteristics n=26 (%) Age * (y), (range) 43.1 ± 8.4 (28-58) Male sex (%) 14 (53.8) Duration of disease * (month), (range) 63 ± 72.7 (3-312) History of underlying disease 7 (26.9) History of allergic disease 22 (84.6) Atopy 17 (68) Angioedema 13 (50) Physical urticaria 13 (50) Atopic dermatitis 14 (53.8) NSAID hypersensitvity 16 (61.5) Family history of allergic disease 8 (30.8) Mean basal UAS * (n=18) (range) 12.11±1.97 (8-15) Mean basal QOL * (n=17) (range) 33.35±13.58 (11-60) Total IgE* (KU/ml) (range) 247.7 ± 274.6 (23-1205) Log total IgE* (KU/ml) (range) 2.18 ± 0.45 (1.36-3.08) ANA 5 (19.2) Anti-thyroglobulin antibody 6 (23.1) Anti-microsomal antibody 1 (7.7) NSAID, nonsteroidal antiinflammatory drug; UAS, urticaria activity score; QOL, quality of life; ANA, antinuclear antibody * Data presented as mean ± SD

Score (mean + SD) 80 UAS CU-QOL P = 0.001 P = 0.004 70 60 50 40 30 20 10 P = 0.001 P = 0.001 0 0 12 24 Anti-IgE antibody treatment (weeks) Figure 1. Changes in urticaria activity score (UAS) and chronic urticaria-specific quality of life (CU-QOL) scores during anti-ige antibody (omalizumab) treatment

Mean ± SD (equivalent dose of loratadine 10 mg/day, mg/week) 300 200 P = 0.001 100 0 0 4 8 12 16 20 24 (weeks) -100 Figure 2. Change in H1-antihistamine requirement during anti-ige antibody treatment

Table 2. Comparison of clinical parameters between remitted and non-remitted groups at week 24 Clinical parameters Group I (n=14) Group II (n=12) P value Age * (y) 43.86±7.33 42.17±9.71 0.595 Male sex (%) 7 (50) 7 (58.3) 0.713 Duration of disease * (month) 78.93±91.84 44.42±36.82 0.494 History of allergic diseases 14 (100) 8 (66.7) 0.033 Atopy 9 (69.2) 8 (66.7) > 0.9 Angioedema 6 (42.9) 7 (58.3) 0.695 Physical urticaria 8 (57.1) 5 (41.7) 0.695 NSAID hypersensitivity 6 (42.9) 10 (83.3) 0.051 Family history of allergic diseases 8 (57.1) 0 0.002 Baseline UAS * (range) 12.78±1.72 11.44±2.07 (8-15) 0.161 Baseline CU-QOL score * (range) 29.1129.11±11.84 40.88±13.32 0.074 Log serum total IgE* (KU/ml) 2.26±0.49 (1.36-2.91) 2.08±0.41 (1.4-3.08) 0.322 NSAID, nonsteroidal anti-inflammatory drug; UAS, urticaria activity score; CU-QOL, chronic urticaria-specific quality of life. * Data are presented as mean ± SD. Subjects who achieved remission at week 24. Subjects who could not achieve remission at week 24.

Recurred, and maintained baseline therapy (n = 5, 19.2%) Remitted group (n = 22, 84.6%) Recurred, but achieved step-down therapy (n = 3, 11.6%) Total enrolled subjects (n = 26) Maintain remission (n = 14, 53.8%) Responsive group (n = 19, 73.1%) Step-down therapy (n = 2, 7.7%) Non-remitted group (n = 4, 15.4%) Refractory state (n = 2, 7.7%) Figure.3. Clinical courses of the subjects

Conclusion Omalizumab is an effective and safe treatment for patients with refractory CU. The findings suggest that a personal or family history of allergic diseases may be a favorable factor for predicting remission. Further studies will be needed to investigate potential factors for differentiating favorable and unfavorable responders.

Question & Discussion